These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 7384184)

  • 1. [The pharmacokinetics of falirytmin given orally to humans].
    Weiss M; Sziegoleit W; Henschke E; von Keyserlingk G; Hafemeister G; Pönicke K; Förster W
    Pharmazie; 1980 Feb; 35(2):123. PubMed ID: 7384184
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetic investigations of Craviten. III. Tissue distribution and elimination in rats.
    Danek A; Witek J
    Pol J Pharmacol Pharm; 1980; 32(6):941-8. PubMed ID: 7243691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic investigations of Craviten. IV. First-pass metabolism in rats.
    Danek A; Witek J
    Pol J Pharmacol Pharm; 1980; 32(6):949-53. PubMed ID: 7243692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro study of (2S, 2'S) N,N'-dimethyl-N, N'-bis [1(3', 4', 5'-trimethoxybenzoyloxy) butyl-2] ethylenediamine salts and their bioavailability.
    Krówczyński L; Kluczykowska B; Stozek T; Wajdowicz A; Bartkowicz S
    Pol J Pharmacol Pharm; 1980; 32(6):909-15. PubMed ID: 7243687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacokinetics of anti-arrhythmics. 1. Fundamental principles].
    Lévy RH
    Arch Mal Coeur Vaiss; 1980 Oct; 73(10):1223-8. PubMed ID: 6778415
    [No Abstract]   [Full Text] [Related]  

  • 6. Relationship between the pharmacokinetics of a short-acting antiarrhythmic drug and its effects: studies with Falirytmin.
    Weiss M; Sziegoleit W; Machill K; Hafemeister G; Förster W
    Int J Clin Pharmacol Ther Toxicol; 1980 Jun; 18(6):237-41. PubMed ID: 7450923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolism of some ethylenediamine derivatives with antiarrhythmic properties. I. Absorption, distribution in tissues and excretion of 14-C labelled N, N'-bis-[3-(p-methoxyphenoxy)-2-hydroxypropyl]-ethylenediamine dimethanesulphonate (MK-142) in rats.
    Nowicka A; Prussak T; Szukalski B
    Pol J Pharmacol Pharm; 1975; 27(2):113-20. PubMed ID: 168561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacokinetics of creatinol-o-phosphate].
    Marzo A; Ghirardi P; Croce G
    Clin Ter; 1972 Sep; 62(5):419-30. PubMed ID: 5085247
    [No Abstract]   [Full Text] [Related]  

  • 9. Metabolic studies of ethylenediamine derivatives: absorption, tissue distribution and elimination of IF-ROM-203-14C compound.
    Nowicka A; Szukalski B; Prussak T; Jahn W
    Mater Med Pol; 1977; 9(3):239-43. PubMed ID: 926839
    [No Abstract]   [Full Text] [Related]  

  • 10. Biochemical, morphochemical and pharmacodynamic evaluation of accumulation of ethylenediamine derivatives (ROM-203, MK-142) in some rat tissues.
    Noyszewska-Skibińska I; Nowicka A; Ernest K; Nowicka J
    Mater Med Pol; 1977; 9(3):216-24. PubMed ID: 926836
    [No Abstract]   [Full Text] [Related]  

  • 11. [Quantitative determination of N,N'-bis-[3-(2'-ethoxyphenoxy)-2-hydroxypropyl]-ethylenediamine dihydrochloride (Falirytmin) in blood].
    Pönicke K; Hauer I; Sziegoleit W; Förster W
    Pharmazie; 1976; 31(9):613-4. PubMed ID: 1019208
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacokinetic data and drug monitoring: I. Antibiotics and antiarrhythmics.
    Chow MS; Ronfeld RA
    J Clin Pharmacol; 1975; 15(5-6):405-18. PubMed ID: 1094037
    [No Abstract]   [Full Text] [Related]  

  • 13. [Effect of Craviten on blood dopamine beta-hydroxylase activity].
    Grabowska M; Gumińska M; Eckstein M
    Folia Med Cracov; 1980; 22(3-4):359-66. PubMed ID: 7286841
    [No Abstract]   [Full Text] [Related]  

  • 14. [Pharmacokinetic parameters of N,N'-bis-(3-(2'-ethoxyphenoxy)-2-hydroxypropy1)-ethylenediamine (Falirytmin) in rabbits].
    Sziegoleit W; Weiss M; Pönicke K; Förster W
    Acta Biol Med Ger; 1976; 35(3-4):521-2. PubMed ID: 970057
    [No Abstract]   [Full Text] [Related]  

  • 15. Serum amiodarone and desethylamiodarone concentrations following nasogastric versus oral administration.
    Kotake T; Takada M; Goto T; Komamura K; Kamakura S; Morishita H
    J Clin Pharm Ther; 2006 Jun; 31(3):237-43. PubMed ID: 16789989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism and pharmacokinetics of ethylenediamine in the rat following oral, endotracheal or intravenous administration.
    Yang RS; Tallant MJ
    Fundam Appl Toxicol; 1982; 2(5):252-60. PubMed ID: 7185622
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of the pharmacokinetics and bioavailability of intravenously and orally administered amiodarone in horses.
    De Clercq D; Baert K; Croubels S; van Loon G; Maes A; Tavernier R; Deprez P; De Backer P
    Am J Vet Res; 2006 Mar; 67(3):448-54. PubMed ID: 16506906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6.
    Dilger K; Greiner B; Fromm MF; Hofmann U; Kroemer HK; Eichelbaum M
    Pharmacogenetics; 1999 Oct; 9(5):551-9. PubMed ID: 10591535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral quinidine therapy for chronic atrial fibrillation.
    Cheng TO
    J Cardiol; 2002 May; 39(5):289-90; author reply 290. PubMed ID: 12048907
    [No Abstract]   [Full Text] [Related]  

  • 20. [Class-1C drugs for oral loading in the cardioversion of paroxysmal atrial fibrillation].
    Capucci A; Rosi A; Villani GQ; Aschieri D; Piepoli M
    G Ital Cardiol; 1998 Dec; 28(12):1422-30. PubMed ID: 9887399
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.